SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19

References

• Chan JFW, To KKW, Tse H, et al. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 2013;21(10):544–555. Epub 2013 Jun 14.
   PubMed Web of Science ®Google Scholar
• Neerukonda SN, Katneni U. A review on SARS-CoV-2 virology, pathophysiology, animal models, and anti-viral interventions. Pathogens. 2020;9(6):426.
   Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
   PubMedGoogle Scholar
• Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–423.
   PubMed Web of Science ®Google Scholar
• Kumar R, Harilal S, Al-Sehemi AG, et al. The chronicle of COVID-19: possible strategies to curb the pandemic. Curr Med Chem. 2020;27. DOI:10.2174/0929867327666200702151018.
   PubMedGoogle Scholar
• Khalaf K, Papp N, Chou JT, et al. SARS-CoV-2: pathogenesis, and Advancements in Diagnostics and Treatment. Front Immunol. 2020;11:570927.
   PubMed Web of Science ®Google Scholar
• V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2020;18:1–16.
   PubMed Web of Science ®Google Scholar
• McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020;7(4):ofaa105.
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018;18(1): 41–58. .
   PubMed Web of Science ®Google Scholar
• Amin SA, Jha T. Fight against novel coronavirus: a perspective of medicinal chemists. Eur J Med Chem. 2020;201:112559.
   PubMed Web of Science ®Google Scholar
• Tan YW, Fung TS, Shen H, et al. Coronavirus infectious bronchitis virus non-structural proteins 8 and 12 form stable complex independent of the non-translated regions of viral RNA and other viral proteins. Virology. 2018;513:75–84.
   PubMed Web of Science ®Google Scholar
• Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun. 2019;10(1):2342. .
   PubMed Web of Science ®Google Scholar
• Gao Y, Yan L, Huang Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368(6492): 779–782. .
   PubMed Web of Science ®Google Scholar
• Chand GB, Banerjee A, Azad GK. Identification of novel mutations in RNA-dependent RNA polymerases of SARS-CoV-2 and their implications on its protein structure. PeerJ. 2020;8:e9492.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wu J, Wang H, et al. Structural basis for RNA replication by the SARS-CoV-2 polymerase. Cell. 2020;182(2):417–428.e13.
   PubMed Web of Science ®Google Scholar
• Mcdonald SM. RNA synthetic mechanisms employed by diverse families of RNA viruses. Wiley Interdiscip Rev RNA. 2013;4(4):351–367.
   PubMed Web of Science ®Google Scholar
• Poch O, Sauvaget I, Delarue M, et al. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. Embo J. 1989;8(12):3867–3874.
   PubMed Web of Science ®Google Scholar
• Smertina E, Urakova N, Strive T, et al. Calicivirus RNA-dependent RNA polymerases: evolution, structure, protein dynamics, and function. Front Microbiol. 2019;10:1280.
   PubMed Web of Science ®Google Scholar
• Gorbalenya AE, Pringle FM, Zeddam JL, et al. The palm subdomain-based active site is internally permuted in viral RNA-dependent RNA polymerases of an ancient lineage. J Mol Biol. 2002;324(1):47–62.
   PubMed Web of Science ®Google Scholar
• Te Velthuis AJW, Arnold JJ, Cameron CE, et al. The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent. Nucleic Acids Res. 2009;38(1):203–214.
   PubMed Web of Science ®Google Scholar
• Hillen HS, Kokic G, Farnung L, et al. Structure of replicating SARS-CoV-2 polymerase. Nature. 2020;584(7819):154–156.
   PubMed Web of Science ®Google Scholar
• Lee NR, Kwon HM, Park K, et al. Cooperative translocation enhances the unwinding of duplex DNA by SARS coronavirus helicase nsP13. Nucleic Acids Res. 2010;38(21):7626–7636.
   PubMed Web of Science ®Google Scholar
• Sevajol M, Subissi L, Decroly E, et al. Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus. Virus Res. 2014;194:90–99.
   PubMed Web of Science ®Google Scholar
• Minskaia E, Hertzig T, Gorbalenya AE, et al. Discovery of an RNA virus 3′→5′ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci USA. 2006;103(13):5108–5113.
   PubMed Web of Science ®Google Scholar
• Ferron F, Subissi L, De Morais ATS, et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci USA. 2017;115:E162–E171.
   PubMed Web of Science ®Google Scholar
• Smith EC, Blanc H, Vignuzzi M, et al. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 2013;9(8):e1003565.
   PubMed Web of Science ®Google Scholar
• de Farias ST, Dos Santos AP, Rêgo TG, et al. Origin and evolution of RNA-dependent RNA polymerase. Front Genet. 2017;8:125.
   PubMed Web of Science ®Google Scholar
• Lam AM, Murakami E, Espiritu C, et al. PSI-7851, a pronucleotide of beta-D-2ʹ-deoxy-2ʹ-fluoro-2ʹ-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother. 2010;54(8):3187–3196.
   PubMed Web of Science ®Google Scholar
• Jockusch S, Tao C, Li X, et al. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Sci Rep. 2020;10(1):16577. Published 2020 Oct 6.
   PubMed Web of Science ®Google Scholar
• Picarazzi F, Vicenti I, Saladini F, et al. Targeting the RdRp of emerging RNA viruses: the structure-based drug design challenge. Molecules. 2020;25(23):5695. Published 2020 Dec 3.
   PubMed Web of Science ®Google Scholar
• Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 2000;6(12):1375–1379.
   PubMed Web of Science ®Google Scholar
• Tzou PL, Tao K, Nouhin J, et al. Coronavirus antiviral research database (CoV-RDB): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds. Viruses. 2020;12(9):1006.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Choy KT, Wong AYL, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786.
   PubMed Web of Science ®Google Scholar
• Pruijssers AJ, George AS, Schäfer A, et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 2020;32(3):107940. .
   PubMed Web of Science ®Google Scholar
• Pizzorno A, Padey B, Julien T, et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell Rep Med. 2020;1(4):100059.
   PubMedGoogle Scholar
• Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819–20.
   PubMed Web of Science ®Google Scholar
• Zandi K, Amblard F, Musall K, et al. Repurposing nucleoside analogs for human coronaviruses. Antimicrob Agents Chemother. 2020;65(1):e01652–20.
   PubMed Web of Science ®Google Scholar
• Xie X, Muruato AE, Zhang X, et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.. Nat Commun. 2020;11(1):5214.
   PubMed Web of Science ®Google Scholar
• Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586(7827):113–119.
   PubMed Web of Science ®Google Scholar
• Bouhaddou M, Memon D, Meyer B, et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell. 2020;182(3):685–712.e19.
   PubMed Web of Science ®Google Scholar
• Cho J, Lee YJ, Kim JH, et al. Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19. Sci Rep. 2020;10(1):16200.
   PubMed Web of Science ®Google Scholar
• Fu L, Ye F, Feng Y, et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun. 2020;11(1):4417.
   PubMed Web of Science ®Google Scholar
• Hahn F, Wangen C, Häge S, et al. IMU-838, a developmental DHODH inhibitor in phase II for autoimmune disease, shows anti-SARS-CoV-2 and broad-spectrum antiviral efficacy in vitro. Viruses. 2020;12(12):1394.
   Web of Science ®Google Scholar
• Hattori SI, Higshi-Kuwata N, Raghavaiah J, et al. GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection. mBio. 2020;11(4):e01833–20.
   PubMed Web of Science ®Google Scholar
• Touret F, Gilles M, Barral K, et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep. 2020;10(1):13093.
   PubMed Web of Science ®Google Scholar
• Ko M, Jeon S, Ryu WS, et al. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2020. DOI:10.1002/jmv.26397.
   Web of Science ®Google Scholar
• De Meyer S, Bojkova D, Cinatl J, et al. Lack of antiviral activity of darunavir against SARS-CoV-2. Int J Infect Dis. 2020;97:7–10.
   PubMed Web of Science ®Google Scholar
• Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273–276.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883.
   PubMed Web of Science ®Google Scholar
• Park SJ, Yu KM, Kim Y Il, et al. Antiviral efficacies of FDA-approved drugs against SARS-COV-2 infection in ferrets. MBio. 2020;11(3):e01114–20.
   PubMed Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385.
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
   PubMed Web of Science ®Google Scholar
• Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep. 2017;7:43395 7.
   Web of Science ®Google Scholar
• Siegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses. J Med Chem. 2017;60(5):1648–1661.
   PubMed Web of Science ®Google Scholar
• Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.
   PubMed Web of Science ®Google Scholar
• Ye W, Yao M, Dong Y, et al. Remdesivir (GS-5734) impedes enterovirus replication through viral RNA synthesis inhibition. Front Microbiol. 2020;11(1):105.
   PubMedGoogle Scholar
• Konkolova E, Dejmek M, Hřebabecký H, et al. Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses. Antiviral Res. 2020;182:104899.
   PubMed Web of Science ®Google Scholar
• Tchesnokov EP, Feng JY, Porter DP, et al. Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019;11(4):326.
   PubMed Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Feng JY, et al. The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773–4779.
   PubMed Web of Science ®Google Scholar
• Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368(6498):1499–1504.
   PubMed Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785–6797.
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–18.
   PubMed Web of Science ®Google Scholar
• Shannon A, Le NTT, Selisko B, et al. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020;178:104793.
   PubMed Web of Science ®Google Scholar
• Pizzorno A, Padey B, Dubois J, et al. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res. 2020;181:104878.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222.
   PubMed Web of Science ®Google Scholar
• de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117(12):6771–6776.
   PubMed Web of Science ®Google Scholar
• Porter DP, Weidner JM, Gomba L, et al. Remdesivir (GS-5734) Is efficacious in cynomolgus macaques infected with marburg virus. J Infect Dis. 2020;222(11):1894–1901.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383:1813–1826.
   Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383:1827–1837.
   Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. J Am Med Assoc. 2020;324(11):1048–1057.
   PubMed Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
   PubMed Web of Science ®Google Scholar
• Antinori S, Cossu MV, Ridolfo AL, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020;158:104899.
   PubMed Web of Science ®Google Scholar
• Olender SA, Perez KK, Go AS, et al. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa1041..
   Google Scholar
• Agostini ML, Pruijssers AJ, Chappell JD, et al. Small-molecule antiviral β-D- N 4 -hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93(24):e01348–1993.
   PubMed Web of Science ®Google Scholar
• Yoon JJ, Toots M, Lee S, et al. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother. 2018;62(8):e00766–18.
   PubMed Web of Science ®Google Scholar
• Painter GR, Bowen RA, Bluemling GR, et al. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res. 2019;171:104597.
   PubMed Web of Science ®Google Scholar
• Urakova N, Kuznetsova V, Crossman DK, et al. β-D- N 4 -hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J Virol. 2018;92(3):e01965–17.
   PubMed Web of Science ®Google Scholar
• Ehteshami M, Tao S, Zandi K, et al. Characterization of β-D-N4-hydroxycytidine as a novel inhibitor of Chikungunya virus. Antimicrob Agents Chemother. 2017;61(4):e02395–1661.
   PubMed Web of Science ®Google Scholar
• Reynard O, Nguyen XN, Alazard-Dany N, et al. Identification of a new ribonucleoside inhibitor of ebola virus replication. Viruses. 2015;7(12):6233–6240.
   PubMed Web of Science ®Google Scholar
• Costantini VP, Whitaker T, Barclay L, et al. Antiviral activity of nucleoside analogues against norovirus. Antivir Ther. 2012;17(6):981–991.
   PubMed Web of Science ®Google Scholar
• Stuyver LJ, Whitaker T, McBrayer TR, et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother. 2003;47(1):244–254.
   PubMed Web of Science ®Google Scholar
• Toots M, Yoon JJ, Cox RM, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019;23(515). DOI:10.1126/scitranslmed.aax5866.
   Google Scholar
• Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser. 2017;93(7):449–463. .
   PubMed Web of Science ®Google Scholar
• Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA. 2010;107(2):882–887.
   PubMed Web of Science ®Google Scholar
• Dawes BE, Kalveram B, Ikegami T, et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci Rep. 2018;8(1):7604.
   PubMedGoogle Scholar
• Oestereich L, Lüdtke A, Wurr S, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17–21.
   PubMed Web of Science ®Google Scholar
• Hawman DW, Haddock E, Meade-White K, et al. Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. Antiviral Res. 2020;181:104858.
   PubMed Web of Science ®Google Scholar
• Fang QQ, Huang WJ, Li XY, et al. Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. Virology. 2020;545:1–9.
   PubMed Web of Science ®Google Scholar
• Wang Y, Anirudhan V, Du R, et al. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. J Med Virol. 2020. Epub ahead of print. DOI:10.1002/jmv.26264..
   Web of Science ®Google Scholar
• Mumtaz N, Jimmerson LC, Bushman LR, et al. Cell-line dependent antiviral activity of sofosbuvir against Zika virus. Antiviral Res. 2017;146:161–163.
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020;6(10):1192–1198.
   PubMedGoogle Scholar
• Gowen BB, Sefing EJ, Westover JB, et al. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res. 2015;121:132–137.
   PubMed Web of Science ®Google Scholar
• Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508(7496):402–405.
   PubMed Web of Science ®Google Scholar
• Julander JG, Siddharthan V, Evans J, et al. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Res. 2017;137:14–22.
   PubMed Web of Science ®Google Scholar
• Taylor R, Kotian P, Warren T, et al. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016;9(3):220–226.
   PubMed Web of Science ®Google Scholar
• Elfiky AA, Ribavirin R, Sofosbuvir G. Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;253:117592.
   PubMed Web of Science ®Google Scholar
• Aftab SO, Ghouri MZ, Masood MU, et al. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J Transl Med. 2020;18(1):275.
   PubMed Web of Science ®Google Scholar
• Zhang WF, Stephen P, Stephen P, et al. Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks. J Phys Chem Lett. 2020;11(11):4430–4435.
   PubMed Web of Science ®Google Scholar
• Witkowski JT, Robins RK, Sidwell RW, et al. Design, synthesis, and broad spectrum antiviral activity of l-(3-D-Ribofuranosyl-l,2,4-triazole-3-carboxamidef and related nucleosides. J Med Chem. 1972;15(11):1150–1154.
   PubMed Web of Science ®Google Scholar
• Lau JYN, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35(5):1002–1009.
   PubMed Web of Science ®Google Scholar
• Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur J Epidemiol. 1986;2(1):1–14.
   PubMedGoogle Scholar
• Khan JA, Rehman S, Fisher-Hoch SP, et al. Crimean congo-haemorrhagic fever treated with oral ribavirin. Lancet. 1995;346(8973):472–475.
   PubMed Web of Science ®Google Scholar
• Falzarano D, De Wit E, Martellaro C, et al. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep. 2020;3:1686.
   Google Scholar
• Swaminathan S, Schlaberg R, Lewis J, et al. Fatal zika virus infection with secondary nonsexual transmission. N Engl J Med. 2016;375(19):1907–1909.
   PubMed Web of Science ®Google Scholar
• Day CW, Baric R, Cai SX, et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009;395(2):210–222.
   PubMed Web of Science ®Google Scholar
• Kim HY, Kong S, Oh S, et al. Benzothiazepinecarboxamides: novel hepatitis C virus inhibitors that interfere with viral entry and the generation of infectious virions. Antiviral Res. 2016;129:39–46.
   PubMed Web of Science ®Google Scholar
• Morgenstern B, Michaelis M, Baer PC, et al. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326(4):905–908.
   PubMed Web of Science ®Google Scholar
• Wilson SZ, Knight V, Wyde PR, et al. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother. 1980;17(4):642–648.
   PubMed Web of Science ®Google Scholar
• Te HS, Randall G, Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol. 2007;3(3):218–225.
   Google Scholar
• Brochot E, Castelain S, Duverlie G, et al. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther. 2010;15(5):687–695.
   PubMed Web of Science ®Google Scholar
• Falzarano D, De Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–1317.
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Falzarano D, Zevenhoven-Dobbe JC, et al. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. Virus Res. 2017;228:7–13.
   PubMed Web of Science ®Google Scholar
• Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. J Biomol Struct Dyn. 2020;1–9. DOI:10.1080/07391102.2020.1761882.
   Web of Science ®Google Scholar
• Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477.
   PubMed Web of Science ®Google Scholar
• Shah NR, Sunderland A, Grdzelishvili VZ. Cell type mediated resistance of vesicular stomatitis virus and sendai virus to ribavirin. PLoS One. 2010;5(6):e11265 5.
   Web of Science ®Google Scholar
• Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704. .
   PubMed Web of Science ®Google Scholar
• Götte M, Feld JJ. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol. 2016;13(6):338–351.
   PubMed Web of Science ®Google Scholar
• Greig SL. Sofosbuvir/Velpatasvir: a review in chronic hepatitis C. Drugs. 2016;76(16):1567–1578.
   PubMed Web of Science ®Google Scholar
• Xu HT, Colby-Germinario SP, Hassounah SA, et al. Evaluation of Sofosbuvir (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine) as an inhibitor of Dengue virus replication. Sci Rep. 2017;7(1):6345.
   PubMedGoogle Scholar
• Mesci P, Macia A, Moore SM, et al. Blocking Zika virus vertical transmission. Sci Rep. 2018;8(1):1218.
   PubMedGoogle Scholar
• Dragoni F, Boccuto A, Picarazzi F, et al. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral Res. 2020;175:104708.
   PubMed Web of Science ®Google Scholar
• Mendes ÉA, Pilger DRB, Santos Nastri ACS, et al. Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure. Ann Hepatol. 2019;18(6):816–824.
   PubMed Web of Science ®Google Scholar
• Ferreira AC, Reis PA, de Freitas CS, et al. Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. Antimicrob Agents Chemother. 2019;63(2):e01389–18.
   PubMed Web of Science ®Google Scholar
• Jiang W, Muhammad F, Ma P, et al. Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system. Antiviral Res. 2018;154:51–57.
   PubMed Web of Science ®Google Scholar
• Ahmad M, Dwivedy A, Mariadasse R, et al. Prediction of small molecule inhibitors targeting the severe acute respiratory syndrome coronavirus-2 RNA-dependent RNA polymerase. ACS Omega. 2020;5(29):18356–18366.
   PubMed Web of Science ®Google Scholar
• Perišić O. Recognition of potential covid-19 drug treatments through the study of existing protein–drug and protein–protein structures: an analysis of kinetically active residues. Biomolecules. 2020;10(9):1–26.
   Web of Science ®Google Scholar
• Chien M, Anderson TK, Jockusch S, et al. Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J Proteome Res. 2020;19(11):4690–4697.
   PubMed Web of Science ®Google Scholar
• Elfiky AA, Azzam EB, Shafaa MW. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico. Mol Divers. 2021;1–11. DOI:10.1007/s11030-020-10178-z
   PubMed Web of Science ®Google Scholar
• Sadeghi A, Ali Asgari A, Norouzi A, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020;75(11):3379–3385.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1–7.
   PubMed Web of Science ®Google Scholar
• Feng JY, Ly JK, Myrick F, et al. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology. 2009;6:44.
   PubMed Web of Science ®Google Scholar
• De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695–747. .
   PubMed Web of Science ®Google Scholar
• Jockusch S, Tao C, Li X, et al. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Res. 2020;180:104857.
   PubMed Web of Science ®Google Scholar
• Good SS, Moussa A, Zhou XJ, et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020;15(1):e0227104.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;NEJMoa2035389. DOI:10.1056/NEJMoa2035389.
   Web of Science ®Google Scholar
• Younes S, Younes N, Shurrab F, et al. Severe acute respiratory syndrome coronavirus-2 natural animal reservoirs and experimental models: systematic review. Rev Med Virol. 2020;e2196. DOI:10.1002/rmv.2196.
   PubMed Web of Science ®Google Scholar
• Lu S, Zhao Y, Yu W, et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct Target Ther. 2020;5(1):157.
   PubMed Web of Science ®Google Scholar
• Lee N, Hurt AC. Neuraminidase inhibitor resistance in influenza: a clinical perspective. Curr Opin Infect Dis. 2018;31(6):520–526.
   PubMed Web of Science ®Google Scholar